Why Most immuno-oncology Programs Fail and What the Next Winners Are Doing Differently

Session details:

As immuno-oncology matures beyond first-generation checkpoint inhibitors, development success is increasingly determined by early biological insight, translational strategy, and portfolio discipline rather than late-stage clinical execution. This panel examines why many IO programs fail to translate promise into differentiated assets, and how leading developers are applying deeper biology, smarter combination logic, and earlier go/no-go decisions to build more credible and capital-efficient pipelines. 

Key discussion points 
Biological differentiation: Selecting mechanisms that address immune resistance, tumor microenvironment complexity, and durability of response. 
Translational rigor and decision-making: Using preclinical and early translational data to inform asset prioritization, combination rationale, and kill decisions. 
Development discipline: Balancing scientific ambition with portfolio focus, capital efficiency, and scalable development strategies.